U.S. Markets close in 5 hrs 40 mins

Isoray, Inc. (ISR)

NYSE American - Nasdaq Real Time Price. Currency in USD
Add to watchlist
0.3699-0.0113 (-2.96%)
As of 10:18AM EDT. Market open.

Isoray, Inc.

350 Hills Street
Suite 106
Richland, WA 99354
United States
509 375 1202

IndustryMedical Devices
Full Time Employees61

Key Executives

NameTitlePayExercisedYear Born
Ms. Lori A. Holmes-WoodsCEO & Director371.19kN/A1962
Ms. Jennifer StreeterCOO & VP of HR266.35kN/A1970
Mr. William A. Cavanagh IIIChief R&D Officer253.34kN/A1966
Mr. Jonathan R. HuntCFO & Co-Principal Financial OfficerN/AN/A1967
Mr. Mark J. Austin CPAVP of Fin., Controller, Co-Principal Financial, Principal Accounting Officer & Sec.N/AN/A1987
Ms. Krista ClineSr. Director of Operations & Corp. Sec.N/AN/A1982
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. Isoray, Inc. was founded in 1998 and is based in Richland, Washington.

Corporate Governance

Isoray, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.